Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
NCT ID: NCT00849290
Last Updated: 2023-11-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
113 participants
INTERVENTIONAL
2004-04-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
APC8015F
APC8015F
APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
APC8015F
APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have been enrolled in the APC-Placebo arm of D9902B (NCT00065442)
Exclusion Criteria
* Treatment with anticancer interventions within 14 days prior to enrollment
* Any medical condition which could compromise the study's objectives (discretion from sponsor)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dendreon
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Schellhammer, MD
Role: STUDY_CHAIR
Devine Tidewater Urology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA
Los Angeles, California, United States
USC Keck School of Medicine
Los Angeles, California, United States
Sutter Cancer Center
Sacramento, California, United States
Kaiser Permanente Medical Group
San Diego, California, United States
Sharp HealthCare
San Diego, California, United States
UCSF Cancer Center
San Francisco, California, United States
Helen F. Graham Cancer Center
Newark, Delaware, United States
Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Walter Reid Army Medical Center
Washington D.C., District of Columbia, United States
Miami Cancer Center
Miami, Florida, United States
Hematology/Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
Georgia Urology, P.A.
Atlanta, Georgia, United States
Midwest Prostate & Urology Health Center
Chicago, Illinois, United States
Loyola University
Maywood, Illinois, United States
Lutheran General Cancer Center
Park Ridge, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Myron I Murdock MD LLC
Greenbelt, Maryland, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Lahey Clinic (Department of Urology)
Burlington, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Nevada Cancer Institute
Las Vegas, Nevada, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Associates in Urology, LLC
West Orange, New Jersey, United States
Albany Regional Cancer Center
Albany, New York, United States
The Urological Institute of Northeastern New York
Albany, New York, United States
North Shore Hematology Oncology Associates
East Setauket, New York, United States
New York Medical College
Hawthorne, New York, United States
Beth Israel Cancer Center
New York, New York, United States
Clinical Cancer Center
New York, New York, United States
Mount Sinai School of Medicine
New York, New York, United States
New York University
New York, New York, United States
Staten Island Urological Research
Staten Island, New York, United States
McKay Urology
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Cincinnati
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
EACRI
Portland, Oregon, United States
Kaiser Permanente Medical Group
Portland, Oregon, United States
Center for Urologic Care
Bryn Mawr, Pennsylvania, United States
Jefferson Medical College
Philadelphia, Pennsylvania, United States
Grand Strand Urology
Myrtle Beach, South Carolina, United States
Mary Crowley
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Urology of Virginia, PC
Norfolk, Virginia, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Cancer Care Northwest
Spokane, Washington, United States
Wenatchee Valley Medical Center
Wenatchee, Washington, United States
University of Wisconsin, Madison
Madison, Wisconsin, United States
University of Wisconsin
Madison, Wisconsin, United States
St. Luke's Hospital Immunotherapy Program
Milwaukee, Wisconsin, United States
Can-Med Medical Research, Inc.
Victoria, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Sunnybrook & Women's College HSC
Toronto, Ontario, Canada
Hospital Notre Dame du CHUM
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
(National Prostate Cancer Coalition)
(USTOO International)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PB01
Identifier Type: -
Identifier Source: org_study_id
NCT00090922
Identifier Type: -
Identifier Source: nct_alias
NCT00170066
Identifier Type: -
Identifier Source: nct_alias
NCT00513006
Identifier Type: -
Identifier Source: nct_alias